These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 26292859)

  • 1. Re: Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer.
    Taneja SS
    J Urol; 2015 Sep; 194(3):704. PubMed ID: 26292859
    [No Abstract]   [Full Text] [Related]  

  • 2. Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer.
    Azad AA; Volik SV; Wyatt AW; Haegert A; Le Bihan S; Bell RH; Anderson SA; McConeghy B; Shukin R; Bazov J; Youngren J; Paris P; Thomas G; Small EJ; Wang Y; Gleave ME; Collins CC; Chi KN
    Clin Cancer Res; 2015 May; 21(10):2315-24. PubMed ID: 25712683
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Has the Time Arrived for Biomarker-Directed Therapy in Castration-Resistant Prostate Cancer?
    Taplin ME; Balk SP
    JAMA Oncol; 2015 Aug; 1(5):577-9. PubMed ID: 26181796
    [No Abstract]   [Full Text] [Related]  

  • 4. ErbB2 Signaling Increases Androgen Receptor Expression in Abiraterone-Resistant Prostate Cancer.
    Gao S; Ye H; Gerrin S; Wang H; Sharma A; Chen S; Patnaik A; Sowalsky AG; Voznesensky O; Han W; Yu Z; Mostaghel EA; Nelson PS; Taplin ME; Balk SP; Cai C
    Clin Cancer Res; 2016 Jul; 22(14):3672-82. PubMed ID: 26936914
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacogenetics of androgen signaling in prostate cancer: Focus on castration resistance and predictive biomarkers of response to treatment.
    Del Re M; Crucitta S; Restante G; Rofi E; Arrigoni E; Biasco E; Sbrana A; Coppi E; Galli L; Bracarda S; Santini D; Danesi R
    Crit Rev Oncol Hematol; 2018 May; 125():51-59. PubMed ID: 29650277
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prostate cancer: AR-V7 status in CTCs is a treatment-specific biomarker.
    Stone L
    Nat Rev Urol; 2016 Aug; 13(8):433. PubMed ID: 27349368
    [No Abstract]   [Full Text] [Related]  

  • 7. [AR-V7 as a predictive biomarker for prostate cancer-more than just prophecy].
    Bernemann C; Krabbe LM
    Urologe A; 2020 Jan; 59(1):80-83. PubMed ID: 31820021
    [No Abstract]   [Full Text] [Related]  

  • 8. Androgen receptor splice variant 7 in castration-resistant prostate cancer: Clinical considerations.
    Bryce AH; Antonarakis ES
    Int J Urol; 2016 Aug; 23(8):646-53. PubMed ID: 27255944
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Choice of new drugs in castration-resistant prostate cancer: predictive factors and effectiveness assessment].
    Basset V; Flamand V; Crouzet S; Ploussard G
    Prog Urol; 2013 Oct; 23 Suppl 1():S44-8. PubMed ID: 24314738
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Castration resistant prostate cancer 2011].
    Miller K
    Aktuelle Urol; 2011 Mar; 42(2):95-102. PubMed ID: 21437832
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Androgen receptor variants in prostate cancer].
    Schreyer E; Barthélémy P; Cottard F; Ould Madi-Berthélémy P; Schaff-Wendling F; Kurtz JE; Céraline J
    Med Sci (Paris); 2017; 33(8-9):758-764. PubMed ID: 28945566
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Molecular biology of castration-resistant prostate cancer].
    Doucet L; Terrisse S; Gauthier H; Pouessel D; Le Maignan C; Teixeira L; Culine S
    Bull Cancer; 2015 Jun; 102(6):497-500. PubMed ID: 26028493
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [ASC-J9 for castration-resistant prostate cancer].
    Yamashita S; Arai Y
    Nihon Rinsho; 2014 Dec; 72(12):2126-9. PubMed ID: 25518345
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diving Into Cabazitaxel's Mode of Action: More Than a Taxane for the Treatment of Castration-Resistant Prostate Cancer Patients.
    Mellado B; Jimenez N; Marin-Aguilera M; Reig O
    Clin Genitourin Cancer; 2016 Aug; 14(4):265-70. PubMed ID: 26827258
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exploitation of the Androgen Receptor to Overcome Taxane Resistance in Advanced Prostate Cancer.
    Martin SK; Kyprianou N
    Adv Cancer Res; 2015; 127():123-58. PubMed ID: 26093899
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Calpain and AR-V7: Two potential therapeutic targets to overcome acquired docetaxel resistance in castration-resistant prostate cancer cells.
    Liu L; Lou N; Li X; Xu G; Ruan H; Xiao W; Qiu B; Bao L; Yuan C; Huang X; Wang K; Cao Q; Chen K; Yang H; Zhang X
    Oncol Rep; 2017 Jun; 37(6):3651-3659. PubMed ID: 28498452
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Contemporary molecular tests for prognosis and treatment guidance for castration-resistant prostate cancer.
    Buonerba C; Di Lorenzo G; Sonpavde G
    Expert Rev Mol Diagn; 2016 Oct; 16(10):1113-1120. PubMed ID: 27665838
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Steroid sidestep: evading androgen ablation by abiraterone.
    Sharifi N
    Clin Cancer Res; 2015 Mar; 21(6):1240-2. PubMed ID: 25432158
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comprehensive Profiling of the Androgen Receptor in Liquid Biopsies from Castration-resistant Prostate Cancer Reveals Novel Intra-AR Structural Variation and Splice Variant Expression Patterns.
    De Laere B; van Dam PJ; Whitington T; Mayrhofer M; Diaz EH; Van den Eynden G; Vandebroek J; Del-Favero J; Van Laere S; Dirix L; Grönberg H; Lindberg J
    Eur Urol; 2017 Aug; 72(2):192-200. PubMed ID: 28104311
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transcript Levels of Androgen Receptor Variant 7 and Ubiquitin-Conjugating Enzyme 2C in Hormone Sensitive Prostate Cancer and Castration-Resistant Prostate Cancer.
    Lee CH; Ku JY; Ha JM; Bae SS; Lee JZ; Kim CS; Ha HK
    Prostate; 2017 Jan; 77(1):60-71. PubMed ID: 27550197
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.